News & Updates

Long-term treatment with indapamide with or without perindopril-based therapy results in a significant reduction in the risk of all-cause mortality, cardiovascular death, fatal stroke, and total stroke among patients with medium to high cardiovascular risk, according to a pooled analysis of four trials.

Cyclophosphamide (CYC) and rituximab (RTX) show comparable therapeutic effects on ear, nose, and throat (ENT) symptoms in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Exposure to any antibiotics appears to contribute to an increase in the risk of esophageal adenocarcinoma (EAC), with the risk rising as the cumulative days of exposure increases, according to a study.

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.